Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181198 | 0.97 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BHPGDTLR7 | |
| SCHEMBL3175429 | 0.96 | ADORA2A (0.53) | ADORA1ADORA2AADORA2BHPGDTLR7 | |
| SCHEMBL3185628 | 0.95 | ADORA1 (0.48) | ADORA1ADORA2AADORA2BHPGDTLR7 | |
| SCHEMBL3176858 | 0.87 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BTLR7PDE4A | |
| SCHEMBL3179033 | 0.86 | ADORA1 (0.45) | ADORA1ADORA2AADORA2BTLR7PDE4A | |
| SCHEMBL3177231 | 0.84 | ADORA1 (0.48) | ADORA1ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL3177612 | 0.83 | ADORA2A (0.49) | ADORA1ADORA2AADORA2BPDE4APDE4B | |
| SCHEMBL3188553 | 0.81 | PDE5A (0.45) | ADORA1ADORA2AADORA2BTLR7PDE4A | |
| SCHEMBL7055376 | 0.78 | ADORA1 (0.48) | ADORA1ADORA2AADORA2BHPGDTLR7 | |
| SCHEMBL3119502 | 0.78 | ADORA1 (0.47) | ADORA1ADORA2AADORA2BADORA3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | claimed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | claimed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | claimed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1781657-B1 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | ADORA1 16/4885ADORA2A 12/4885ADORA2B 50/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA1 17/4885ADORA2A 8/4885ADORA2B 60/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA1 17/4885ADORA2A 8/4885ADORA2B 60/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA1 17/4885ADORA2A 8/4885ADORA2B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.